Shares of TG Therapeutics Inc. (NASDAQ:TGTX) were up 3.6% during mid-day trading on Wednesday . The company traded as high as $5.89 and last traded at $5.83, with a volume of 150,496 shares trading hands. The stock had previously closed at $5.63.

A number of analysts have recently issued reports on TGTX shares. Brean Capital reaffirmed a “buy” rating on shares of TG Therapeutics in a report on Tuesday, June 7th. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a report on Thursday, April 14th. SunTrust Banks Inc. started coverage on shares of TG Therapeutics in a report on Friday, May 27th. They set a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research downgraded shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. Finally, Roth Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Thursday, June 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $22.33.

The firm’s market cap is $320.68 million. The stock has a 50-day moving average price of $6.71 and a 200-day moving average price of $8.22.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. On average, analysts expect that TG Therapeutics Inc. will post ($1.15) EPS for the current year.

A hedge fund recently raised its stake in TG Therapeutics stock. New York State Common Retirement Fund raised its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 as of its most recent filing with the SEC.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.